Abstract:STUDY HYPOTHESIS: Detailed structural comparisons of sperm-specific glyceraldehyde 3-phosphate dehydrogenase, spermatogenic (GAPDHS) and the somatic glyceraldehyde 3-phosphate dehydrogenase (GAPDH) isozyme should facilitate the identification of selective GAPDHS inhibitors for contraceptive development.STUDY FINDING: This study identified a small-molecule GAPDHS inhibitor with micromolar potency and >10-fold selectivity that exerts the expected inhibitory effects on sperm glycolysis and motility.WHAT IS KNOWN ALREADY: Glycolytic ATP production is required for sperm motility and male fertility in many mammalian species. Selective inhibition of GAPDHS, one of the glycolytic isozymes with restricted expression during spermatogenesis, is a potential strategy for the development of a non-hormonal contraceptive that directly blocks sperm function.STUDY DESIGN, SAMPLES/MATERIALS, METHODS: Homology modeling and x-ray crystallography were used to identify structural features that are conserved in GAPDHS orthologs in mouse and human sperm, but distinct from the GAPDH orthologs present in somatic tissues. We identified three binding pockets surrounding the substrate and cofactor in these isozymes and conducted a virtual screen to identify small molecule compounds predicted to bind more tightly to GAPDHS than to GAPDH. Following the production of recombinant human and mouse GAPDHS, candidate compounds were tested in dose-response enzyme assays to identify inhibitors that blocked the activity of GAPDHS more effectively than GAPDH. The effects of a selective inhibitor on the motility of mouse and human sperm were monitored by computer-assisted sperm analysis, and sperm lactate production was measured to assess inhibition of glycolysis in the target cell.MAIN RESULTS AND THE ROLE OF CHANCE: Our studies produced the first apoenzyme crystal structures for human and mouse GAPDHS and a 1.73 angstrom crystal structure for NAD+-bound human GAPDHS, facilitating the identification of unique structural features of this sperm isozyme. In dose-response assays T0501_7749 inhibited human GAPDHS with an IC50 of 1.2 mu M compared with an IC50 of 38.5 mu M for the somatic isozyme. This compound caused significant reductions in mouse sperm lactate production (P = 0.017 for 100 mu M T0501_7749 versus control) and in the percentage of motile mouse and human sperm (P values from <0.05 to <0.0001, depending on incubation conditions).LIMITATIONS, REASONS FOR CAUTION: The chemical properties of T0501_7749, including limited solubility and nonspecific protein binding, are not optimal for drug development.WIDER IMPLICATIONS OF THE FINDINGS: This study provides proof-of-principle evidence that GAPDHS can be selectively inhibited, causing significant reductions in sperm glycolysis and motility. These results highlight the utility of structure-based drug design and support further exploration of GAPDHS, and perhaps other sperm-specific isozymes in the glycolytic pathway, as contraceptive targets.LARGE SCALE DATA: None. Coordinates and data files for three GAPDHS crystal structures were deposited in the RCSB Protein Data Bank (http://www.rcsb.org).

In silico discovery of potential inhibitors targeting the MEIG1-PACRG complex for male contraceptive development

Pharmacophore based virtual screening for identification of effective inhibitors to compact HPV 16 E6 a triggered cervical cancer

Binding Interactions of Epididymal Protease Inhibitor and Semenogelin-1: a Homology Modeling, Docking and Molecular Dynamics Simulation Study

Interactions of the male contraceptive target EPPIN with semenogelin-1 and small organic ligands

A single amino acid mutation in the mouse MEIG1 protein disrupts a cargo transport system necessary for sperm formation

Structural Analyses to Identify Selective Inhibitors of Glyceraldehyde 3-Phosphate Dehydrogenase-S, a Sperm-Specific Glycolytic Enzyme

The novel BRDT inhibitor NHWD870 shows potential as a male contraceptive in mice.

The Control Of Male Fertility By Spermatid-Specific Factors: Searching For Contraceptive Targets From Spermatozoon'S Head To Tail

On-demand male contraception via acute inhibition of soluble adenylyl cyclase

Virtual screening and molecular dynamics simulations of phytochemicals targeting cofactor-independent phosphoglycerate mutase in antimicrobial-resistant Mycoplasma genitalium

Rapid identification of dual p53-MDM2/MDMX interaction inhibitors through virtual screening and hit-based substructure search

Targeting nuclear receptor corepressors for reversible male contraception

Novel Genes of the Male Reproductive System: Potential Roles in Male Reproduction and as Non‐hormonal Male Contraceptive Targets

Effective Screening Strategy Using Ensembled Pharmacophore Models Combined with Cascade Docking: Application to P53-Mdm2 Interaction Inhibitors

Unraveling the Molecular Targets Pertinent to Junction Restructuring Events During Spermatogenesis Using the Adjudin-Induced Germ Cell Depletion Model

A Cocktail-Inspired Male Birth Control Strategy with Physical/Chemical Dual Contraceptive Effects and Remote Self-Cleared Properties

Ion-channels in Human Sperm Membrane and Contraceptive Mechanisms of Male Antifertility Compounds Derived from Chinese Traditional Medicine

Computational Study On Natural Compounds Inhibitor Of C-Myc

In silico design and ADMET evaluation of new inhibitors for PIM1 kinase using QSAR studies, molecular docking, and molecular dynamic simulation

Exploring the Potential of Plant Bioactive Compounds against Male Infertility: An In Silico and In Vivo Study

In silico exploration of PD-L1 binding compounds: Structure-based virtual screening, molecular docking, and MD simulation